Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ALKYLATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,207 records · Page 67Linked to original sources

[Directed modification of the early region of T7 bacteriophage DNA by alkylation in the R-loop formed by a modified transcript].

For addressed modification of T7 phage DNA a polyalkylating derivative of T7 phage early transcript was used. The derivative was obtained by attaching polyfunctional alkylating agent N,N,N,'-tri(beta-chloroethyl)-N'-(p-formylphenyl) propylene diamine-1,3 to the transcript, their molecules being covalently bound by alkylating 4--5% of the RNA adenine and guanine residues. The polyalkylating RNA was used to form R-loops in the complementary site of T7 DNA to alkylate selectively the T7 phage early DNA. Alkylation of DNA by the modified transcript in the region of the R-loop led to the covalent binding of the transcript to the complementary site of DNA. The correct localization of this R-loop was confirmed by electron microscopy. The application of the results for the addressed mutagenesis and inactivation of selected genes is discussed.

Alkylation↗

Outcomes of thirty-four rheumatoid arthritis patients with renal amyloidosis, including twelve given alkylating agents.

We reviewed 34 cases of rheumatoid arthritis with biopsy-proven renal amyloidosis. Mean age was 57.1 +/- 13 years and mean duration of rheumatoid arthritis was 13.7 +/- 8.2 years. Renal function tests done at the time of diagnosis of amyloidosis were available for 32 patients and showed renal failure in 16. Twelve patients received an alkylating agent. Twenty patients (59%) died, after a mean interval of 25.7 +/- 25.1 months since the diagnosis of renal amyloidosis; 19 of these patients (95%) had renal failure. Seven of the 14 survivors and four of the 11 survivors with impaired renal function were given an alkylating agent; mean follow-up since the diagnosis of renal amyloidosis was 77.2 +/- 58.7 months. At completion of the study, renal function was normal in only three patients, all of whom received an alkylating agent. Our data confirms the bleak prognosis of renal amyloidosis in rheumatoid arthritis patients and suggests a need for randomized trials designed to evaluate the efficacy of alkylating agents in this condition.

Adult↗

Synthesis, DNA binding, and sequence specificity of DNA alkylation by some novel cyclic peptide-chlorambucil conjugates.

In an effort to investigate the potential of cyclic peptides as carriers for cytotoxic agents, we synthesized four cyclic peptide-chlorambucil conjugates: cyclo[Lys(CHB)-Lys(CHB)-Gaba-] (peptide Y), cyclo[Lys(CHB)-Gly-Lys(CHB)-Gaba-] (peptide A), cyclo[Lys(CHB)-beta-Ala-Lys(CHB)-Gaba-] (peptide B) and cyclo[Lys(CHB)-Gaba-Lys(CHB)-Gaba-] (peptide C). The cyclic peptides were synthesized by coupling protected amino acid residues in solution and the subsequent cyclization was performed by the pentafluorophenyl ester method as described previously (Sheh et al., 1990, 1993a,b). After deblocking the lysyl-carbobenzyloxy protecting group (Z), the conjugation was achieved by reaction with the pentafluorophenyl ester of chlorambucil (CHB). These cyclic peptides differ from one another in ring size and are disubstituted with CHB via the epsilon-amino group of the lysyl residue. The various conjugates were designed to study the effect of ring size on the mode of DNA binding and alkylation. A DNA-binding assay using lambda-DNA with ethidium bromide showed that whereas peptide Y and CHB have no observable binding affinity, the apparent binding constants for peptide A, peptide B and peptide C on lambda-DNA were determined to be 2.36 x 10(5), 1.27 x 10(5) and 3.50 x 10(5), respectively. Thus, it is suggested that cyclic peptides bearing aliphatic side chains attached to a ring larger in size than 14 members would be more favourable as regards augmenting the binding affinity. DNase I footprinting showed that no footprinting patterns were observed for the 253-mer fragment and 117-mer fragment with peptide A, but two new bands corresponding to G69 and G80 were observed for the 117-mer fragment. DNA alkylation studies using a piperidine cleavage assay on the 117-mer DNA fragment showed that the sequence selectivity, judged by reaction intensity observed with peptide A, peptide B and peptide C, was similar to that seen with CHB alone. The selectivity of alkylation for both CHB and its peptide derivatives appears to be: 3'-Pur-G-Pyr-5' > 3'-Pyr-G-Pyr-5' > 3'-Pyr-G-Pur-5' = 3'Pur-G-Pur-5'. However, there are apparent differences in the intensity of alkylation by peptides A, B, C and CHB at certain guanine residues.

Alkylation↗

In vitro suppression of leukemia by alkylated interleukin-3.

We report the in vitro suppression of the IL-3-dependent MO-7 acute myeloid leukemia proliferation by an interleukin-3 antagonist. The antagonist was generated by alkylation to inactivate catalytic His-residues of native human interleukin-3. The resulting inhibitor caused a factor 7 inhibition of the growth-response curve of the IL-3 control-stimulated proliferation of a MO-7 leukemia cell line. A 40% inhibition of the MO-7 proliferation could be achieved with a partially alkylated inhibitor in presence of a factor 30 excess of native IL-3. Therefore, the inhibitor had a substantially improved affinity for the IL-3 receptor on these leukemia cells. At a concentration of as low as 0.1 ng/ml it still caused a 2-fold inhibition of the native IL-3-stimulated proliferation response curve. Thus it can be concluded that this alkylate IL-3 is a potent IL-3 antagonist. Based on the reported specific zinc binding of IL-2, IL-6, GM-CSF and gamma-interferon this suggests that more leukemias and even other forms of cancer can be effectively suppressed by alkylated growth factors.

Acute Disease↗

Mapping of DNA alkylation sites induced by aziridinylbenzoquinones in human cells by ligation-mediated polymerase chain reaction.

Diaziridinylbenzoquinones such as 3,6-diaziridinyl-1,4-benzoquinone (DZQ) and its 2,5-methyl analog (MeDZQ) require bioreductive activation in order to elicit their cytotoxic activities. In this study, we have mapped the intracellular alkylation sites induced by DZQ and MeDZQ in a single copy gene at the nucleotide level using ligation-mediated polymerase chain reaction. We have performed this analysis in two human colon carcinoma cells, one proficient (HT-29) and one deficient (BE) in DT-diaphorase (DTD) activity. In the DTD-proficient HT-29 cell line, DZQ and MeDZQ were found to alkylate both 5'-(A/T)G(C)-3' and 5'-(A/T)A-3' sequences. This is consistent with the nucleotide preferences observed when DZQ and MeDZQ are activated by purified DTD to reactive metabolites capable of alkylating DNA in vitro (C-S. Lee, J. A. Hartley, M. D. Berardini, J. Butler, D. Siegel, D. Ross, and N. W. Gibson. Biochemistry, 31: 3019-3025, 1992). Surprisingly in the DTD-deficient BE cell line a pattern of alkylation induced by DZQ and MeDZQ similar to that observed in the DTD-proficient HT-29 cells was observed. This suggests that reductive enzymes other than DTD can be involved in activating DZQ and MeDZQ to DNA-reactive species in vivo.

Alkylation↗

In vivo mutagenesis induced by CC-1065 and adozelesin DNA alkylation in a transgenic mouse model.

Although considerable work has focused on characterizing the bonding chemistry and sequence selective alkylation of DNA by cyclopropylpyrroloindole compounds, little is known about the molecular consequence of their N-3-adenine adducts in whole animal systems. We have utilized a transgenic mouse system, harboring a lambda phage shuttle vector, to assess the mutagenic potential of the antitumor compounds CC-1065 and adozelesin and, for the first time, to track the in vivo fate of their unique DNA modifications at the nucleotide level. Mice were inoculated with a single therapeutic dose of these agents and sacrificed at either 18 h, 3 days, or 15 days for extraction and analysis of liver DNA. Mutant frequencies obtained from drug treated and control animals were determined by in vitro packaging of the phage vector from genomic DNA followed by a colorimetric plaque assay to screen for phage in which the accompanying lacI repressor gene had mutated. Although undetectable at 18 h posttreatment, by 72 h a 3-fold increase in mutant frequency was observed in drug treated animals such that sequence analysis of drug induced mutations could be performed and a direct comparison made between in vitro and in vivo DNA alkylation. Base substitution involving guanine or cytosine accounted for 64% of the 41 mutations sequenced from drug treated animals. Only 7 of the mutations occurred at a cyclopropylpyrroloindole alkylation site while 23 occurred 1 to 4 nucleotides from a potentially alkylated adenine.

Alkylation↗

Multidrug resistance is a component of V79 cell resistance to the alkylating agent adozelesin.

Adozelesin is a highly potent alkylating agent which has entered clinical trials based on its unique mechanisms of action and broad-spectrum antitumor activity in vivo. V79 cells resistant to adozelesin (V79/AdoR) were not resistant to the alkylating agent cisplatin but showed the phenotypic and genotypic characteristics of multidrug resistance. Thus V79/AdoR was cross-resistant to several structurally and functionally unrelated drugs, resistance was reversed by verapamil, and the resistant cell line expressed mdr mRNA and p170 glycoprotein. Also, adozelesin uptake and the amount of drug alkylated to DNA was much lower in the resistant cell line as compared to the sensitive parent. However, even with the same amount of drug bound to DNA (10 fmol/micrograms DNA) the survival of V79/S approximately 15% survival) was much lower than that of V79/AdoR (approximately 80%). Therefore the resistance of V79/AdoR cannot be explained solely by the multidrug resistance mechanism (i.e., lower drug uptake and less drug alkylation to DNA), which suggests that multiple mechanisms may account for resistance to adozelesin. V79/AdoR showed different levels of cross-resistance to several adozelesin analogues. The analogues could be divided into 2 groups; those with very low partition coefficients (log P < 2 as compared to 2.74 for adozelesin) had low levels of cross-resistance, whereas analogues with higher partition coefficients (log P > 2.4) were cross-resistant to adozelesin.

Alkylating Agents↗

DNA topoisomerase II alpha expression is associated with alkylating agent resistance.

Increased expression of DNA topoisomerase II alpha has been associated with resistance to certain DNA-damaging alkylating agents, but no causal relationship or mechanism has been established. To investigate this observation, we developed a model of topoisomerase II overexpression by transfecting a full-length Chinese hamster ovary topoisomerase II alpha into EMT6 mouse mammary carcinoma. Topoisomerase II alpha-transfected cell lines demonstrated continued topoisomerase II alpha mRNA and protein expression, which were undetectable in vector-only lines, in stationary phase (G0-G1). The topoisomerase II transfectants were approximately 5-10-fold resistant to the alkylating agents cisplatin and mechlorethamine. Upon release from G0-G1, the topoisomerase II transfectants demonstrated more rapid thymidine incorporation and shorter cell-doubling times than control cells. Purified topoisomerase II and nuclear extracts with topoisomerase II-decatenating activity bound to cisplatin-treated DNA with significantly greater affinity than to untreated DNA in a cisplatin concentration-dependent manner. These observations suggest that expression of topoisomerase II alpha may have a role in cellular resistance to antineoplastic alkylating agents. The mechanism for this may involve increased binding of topoisomerase II alpha to alkylating agent-damaged DNA.

Animals↗

Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing.

In Escherichia coli, the repair of 3-methyladenine (3MeA) DNA lesions prevents alkylation-induced cell death because unrepaired 3MeA blocks DNA replication. Whether this lesion is cytotoxic to mammalian cells has been difficult to establish in the absence of 3MeA repair-deficient cell lines. We previously isolated and characterized a mouse 3MeA DNA glycosylase cDNA (Aag) that provides resistance to killing by alkylating agents in E. coli. To determine the in vivo role of Aag, we cloned a large fragment of the Aag gene and used it to create Aag-deficient mouse cells by targeted homologous recombination. Aag null cells have no detectable Aag transcripts or 3MeA DNA glycosylase activity. The loss of Aag renders cells significantly more sensitive to methyl methanesulfonate-induced chromosome damage, and to cell killing induced by two methylating agents, one of which produces almost exclusively 3MeAs. Aag null embryonic stem cells become sensitive to two cancer chemotherapeutic alkylating agents, namely 1,3-bis(2-chloroethyl)-1-nitrosourea and mitomycin C, indicating that Aag status is an important determinant of cellular resistance to these agents. We conclude that this mammalian 3MeA DNA glycosylase plays a pivotal role in preventing alkylation-induced chromosome damage and cytotoxicity.

Alkylating Agents↗

Novel DNA-directed alkylating agents consisting of naphthalimide, nitrogen mustard and lexitropsin moieties: synthesis, DNA sequence specificity and biological evaluation.

Novel DNA-directed alkylating agents comprising naphthalimide, nitrogen mustard and lexitropsin moieties have been designed, synthesized and characterized. Their properties have been evaluated with respect to DNA binding ability, sequence preference, influence of flanking sequences on alkylation efficiency and cytotoxic potency against KB human nasopharangeal tumour cells. The results indicate that, in contrast to distamycin and bis-benzimidazole-bearing nitrogen mustard moieties where DNA alkylation is directed to adenine N3 sites in the minor groove, the naphthalimide nitrogen mustards alkylate DNA at accessible guanine N7 sites within the major groove. Structural factors that may affect cytotoxic efficacy are discussed.

1-Naphthylamine↗

Synthesis, DNA binding, cytotoxicity and sequence specificity of a series of imidazole-containing analogs of the benzoic acid mustard distamycin derivative tallimustine containing an alkylating group at the C-terminus.

In an attempt to produce additional alkylation and crosslinking in the minor groove of DNA, imidazole-containing analogs of distamycin were synthesized with benzoic acid mustard (BAM) and methoxyaziridinyl moieties present at the N- and C-termini, respectively. Analogs 1a-c differed in the number of methylene units (2-4 respectively) between the C-terminal carbonyl group and the methoxyaziridinyl moiety. DNA binding affinity to several polynucleotides decreased with increasing linker length, whereas DNA interstrand crosslinking ability, as measured by a plasmid gel based assay, increased. The in vitro cytotoxicity in human chronic myeloid leukemia K562 cells and the panel of human tumor cell lines at the National Cancer Institute decreased with increasing number of methylene units, and no increase in cytotoxicity was observed over compound AR-1-122 which did not contain the methoxyaziridinyl moiety. 1a-c had the same sequence selectivity of alkylation as AR-1-122, showing alkylation only at 5'-TTTTGPu sequences. The relative binding to these sequences decreased with increasing number of methylene units. The addition of a methoxyaziridinyl moiety in this group of imidazole and BAM-containing compounds can, therefore, increase crosslinking ability to naked DNA but this does not result in an increase in cytotoxicity. In contrast the cytotoxicity was related to their ability to produce sequence specific alkylation at 5'-TTTTGPu sequences.

Alkylating Agents↗

Studies on the mechanism of DNA sequence selective alkylation by kapurimycin A3 analogs.

We synthesized kapurimycin A3 ABCD-ring analog and compared the sequence selectivity for DNA guanine alkylation with those of kapurimycin A3 and ABC-ring analog. In the binding to DNA, it was shown by DNA unwinding assay that ABCD-ring analog binds tightly to DNA by intercalation into DNA duplex. DNA alkylation by ABCD-ring analog was sequence selective with an order of G*G > G*A > G*T > G*C. ABCD-ring analog has a stronger binding ability, a higher reactivity to DNA and a higher GG sequence selectivity in DNA alkylation than those to ABC-ring analog. The aromatic ring system plays an important role in the effective GG selective alkylation.

Alkylation↗

C-C bond-forming reactions of Ir(III)-alkenyls and nitriles or aldehydes: generation of reactive hydride- and alkyl-alkylidene compounds and observation of a reversible 1, 2-H shift in stable hydride-Ir(III) alkylidene complexes.

Nucleophilic attack of the beta-carbon of an Ir(III)-alkenyl functionality onto the alpha-carbon of a coordinated nitrile- or aldehyde occurs intramoleculary to yield initially iridacyclic structures. Nitriles give rise to isolable complexes that contain delocalized five-membered rings (iridapyrroles, e.g. 3'-8') in a reaction catalyzed by H2O (for some of these syntheses, Ir(III)-eta 3-allyl derivatives may be used as the source of the Ir(III)-alkenyl moiety). In contrast, the alkenyl-to-aldehyde C-C coupling gives transient iridacycles that evolve by a fast alkyl-to-alkylidene migration and beta-H elimination. The end products (13* and 14*) contain an elaborated chelating alkoxide-olefin ligand. Addition of [H(OEt2)2][BAr'4] to the iridapyrroles effects stereospecific protonation of the beta-ring carbon. Those iridapyrroles which contain an additional metal-alkyl functionality (e.g. 3a*, alkyl = C2H5) afford highly reactive cationic alkyl-alkylidene intermediates that evolve instantaneously by migratory insertion/beta-H elimination. The end products also contain an elaborated, chelating ligand, although this time with an olefin and imine terminus compared with the previous ligand. Contrary to this result, protonation of the hydride-iridapyrrole complex 8a* in weakly coordinating solvents permits isolation of two unusual cationic cis-hydride-alkylidene compounds 11*, which undergo reversible 1,2-H shifts.

Journal Article↗

1-Aryl-N2-alkyl-ethanediamines as isosters of adrenergic arylethanolamines.

A family of 1-aryl-N2-alkyl-ethanediamines 1 isosteric with the N-alkyl-arylethanolamines are described. Although the prepared compounds were generally less potent than the N-alkyl-arylethanolamines, the 1-aryl-N'-(phenylmethyl)-N-alkyl-1,2-ethanediamines derivatives 6, are more active than the debenzylated free amino analogs 1, which may be indicative of the importance of the lipophilicity of the substituent at the alpha position to the aromatic ring.

Adenylyl Cyclases↗

Tetrabutylammonium decatungstate-photosensitized alkylation of electrophilic alkenes: Convenient functionalization of aliphatic C-H bonds.

Tetrabutylammonium decatungstate (TBADT, 2 x 10(-3) m) is an effective photocatalyst for the alkylation of electrophilic alkenes (0.1 m, alpha,beta-unsaturated nitriles, esters, ketones) by alkanes, alcohols, and ethers. The products are in most cases obtained in >70 % isolated yields, through an experimentally very simple procedure. The kinetics of the radical processes following initial hydrogen abstraction by excited TBADT in deoxygenated MeCN have been studied. In the absence of a trap, back hydrogen transfer from reduced tungstate is the main pathway for alkyl radicals, while alpha-hydroxyalkyl radicals are oxidized to ketones by ground-state TBADT. With both radical types the reaction ceases at a few percent conversion. However, trapping by electrophilic alkenes is followed by reduction of the radical adduct and regeneration of the catalyst, which allows the alkylation to proceed up to complete alkene conversion with the mentioned good yields of products. With a nucleophilic (alpha-hydroxyalkyl) radical, alkylation is efficient (Phi = 0.58) and can also be carried out when degassing is omitted, the only difference being a short induction period. With a less reactive (cyclohexyl) radical, the quantum yield is lower (Phi = 0.06) and the reaction is considerably slowed in aerated solutions, but the chemical yield remains good.

Journal Article↗

Sensitive and selective photoinduced-electron-transfer-based sensing of alkylating agents.

Photoinduced-electron-transfer (PET)-based chemosensing is a very elegant way of reporting the presence of a guest species in solution. This method was successfully applied for the detection of different ionic species, such as cations, anions, and protons. Herein, we report on the application of the PET chemosensing concept for the efficient and selective detection of different alkylating agents. 2-(2-Dimethylaminoethyl)benzo[de]isoquinoline-1,3-dione (1) was found to be a highly selective and effective PET chemosensor that turns luminescent upon reacting with different alkylating agents. This PET-based system detected even rather weak alkylating agents, such as dichloromethane. A PET-based sensor that consists of 1 as the active component could detect rather low concentrations of alkylating agents in solution and in the gas phase.

Journal Article↗

Well-defined cationic alkyl- and alkoxide-aluminum complexes and their reactivity with epsilon-caprolactone and lactides.

We describe the synthesis, structure, and reactivity of low-coordinate Al-alkyl and -alkoxide cationic complexes incorporating the sterically bulky aminophenolate bidentate ligand 6-(CH(2)NMe(2))-2-CPh(3)-4-Me-C(6)H(2)O- (N,O). These complexes are derived from the ionization of neutral dialkyl Al complexes (N,O)Al2) (1 a, R=Me; 1 b, R=iBu), readily obtained by alkane elimination between AlR3 and the corresponding aminophenol ligand, with the alkyl abstracting reagents B(C(6)F(5))3 and [Ph(3)C][B(C(6)F(5))4]. The reactions of 1 a,b with B(C(6)F(5))3 yield complicated mixtures or decomposition products, however the ionization of the Al-diisobutyl derivative 1 b with [Ph(3)C][B(C(6)F(5))4] affords a stable four-coordinate Al-PhBr cationic adduct [(N,O)Al(iBu)(PhBr)]+ (3+), as deduced from elemental analysis data. Complex 3+ readily coordinates Lewis bases such as THF to form the corresponding adduct [(N,O)Al(iBu)(thf)]+ (4+), and also rapidly chain-transfers with 1-hexene to yield the three-coordinate Al-hexyl cation [(N,O)Al-hexyl]+ (5+). Both cations 3+ and 5+ slowly dimerize to form unprecedented organoaluminum dications [(N,O)AlR+]2 (3'++, R=iBu; 5'++, R=hexyl) as deduced from X-ray crystallographic analysis. Cation 3+ reacts quickly with iPrOH to form a stable Lewis acid/base adduct [(N,O)Al(iBu)(HOiPr)]+ (6+), which constitutes the first X-ray characterized adduct between an Al-alkyl complex and a simple ROH. The Al-ROH proton in 6+ is readily abstracted by NMe(2)Ph to form the neutral isopropoxide Al complex [(N,O)Al(iBu)(OiPr)] (7). Upon reaction with THF, cation 6+ undergoes an intramolecular proton transfer to yield the ammonium Al-THF complex [(eta1-HN,O)Al(iBu)(OiPr)(thf)] (8 b+), in which the aminophenolate is eta1-coordinated to the Al center. Cation 8 b+ can then be converted to the desired Al-alkoxide derivative [(N,O)Al(OiPr)(thf)](+) (10+), by an intramolecular protonolysis reaction, as confirmed by X-ray crystallography. The synthesized Al-alkyl cations form robust four-coordinate adducts in the presence of cyclic esters such as epsilon-caprolactone and (D,L)-lactide, but no insertion chemistry occurs, illustrating the poor ability of the Al-R+ moiety to ring-open. In contrast, the Al-alkoxide cation 10+ polymerizes epsilon-caprolactone in a controlled manner with excellent activity, but is inactive in the polymerization of (D,L)-lactide and L-lactide. Control experiments with L-lactide show that cation 10+ ring-opens L-lactide to yield a robust five-coordinated Al--lactate cation [(N,O)Al(eta2-L-lactate-OiPr)(thf)]+ (13+), derived from a monoinsertion of L-lactide into the Al--OiPr bond of 10+, that does not further react. Cation 13+ may be regarded as a structurally characterized close mimic of the initial intermediate in the ring opening polymerization (ROP), of lactides by [{LX}M(OR)(L)] (where LX-=bidentate monoanionic ligand and L=labile ligand) metal complex initiators.

Journal Article↗

Relation between structure and antimicrobial activity of 2-(N,N,N-trialkylammonio)alkyl hydrogen phosphates.

A series of phosphobetaines [2-(N,N,N-trialkylammonio)alkyl hydrogen phosphates], having different alkyl chains and a methylene bridge separating the phosphate and ammonio group, was investigated in order to provide a new antimicrobial agent. Maximal activity was obtained with the compound having a hexadecyl group as a long-chained alkyl group, two methyl groups as short-chained alkyl groups, and a dimethylene bridge as an intercharge distance. In contrast, sodium 2-(N-hexadecyl-N-methylamino)ethyl hydrogen phosphate, 2-(N-hexadecyl-N,N-dimethylammonio)-1-hydroxyethyl iodide, and N-octadecyl-N,N-dimethylammonio acetate showed decreased activity, indicating that the presence of a phosphobetaine moiety was essential for activity. Thus, 2-(N-hexadecyl-N,N-dimethylammonio)ethyl hydrogen phosphate has been found to possess strong antimicrobial activity and a broad antimicrobial spectrum against nine kinds of bacteria (e.g., fungi, yeast, gram-negative and gram-positive bacteria), which are comparable with those of chlorhexidine digluconate.

Anti-Bacterial Agents↗